Diagnostic tests in urology: Percentage of free prostate-specific antigen (PSA)

Yooni Yi; Rodney H. Breau; Kelsey Witiuk; Molly M. Neuberger; Philipp Dahm

doi:10.1111/j.1464-410X.2012.11446.x

Diagnostic tests in urology: Percentage of free prostate-specific antigen (PSA)

Yooni Yi, Rodney H. Breau, Kelsey Witiuk, Molly M. Neuberger, Philipp Dahm

Urology

Research output: Contribution to journal › Article › peer-review

Abstract

What's known on the subject? and What does the study add? Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood. This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.

Original language	English (US)
Pages (from-to)	683-685
Number of pages	3
Journal	BJU International
Volume	111
Issue number	4
DOIs	https://doi.org/10.1111/j.1464-410X.2012.11446.x
State	Published - Apr 2013

Keywords

diagnostic test
elevated PSA
evidence-based medicine
percentage of free prostate-specific antigen
prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/j.1464-410X.2012.11446.x

OpenUrl availability

Full text

Cite this

@article{3ba523a893a64ef1952bd00ddc1d3b6d,

title = "Diagnostic tests in urology: Percentage of free prostate-specific antigen (PSA)",

abstract = "What's known on the subject? and What does the study add? Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood. This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.",

keywords = "diagnostic test, elevated PSA, evidence-based medicine, percentage of free prostate-specific antigen, prostate cancer",

author = "Yooni Yi and Breau, {Rodney H.} and Kelsey Witiuk and Neuberger, {Molly M.} and Philipp Dahm",

year = "2013",

month = apr,

doi = "10.1111/j.1464-410X.2012.11446.x",

language = "English (US)",

volume = "111",

pages = "683--685",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Diagnostic tests in urology

T2 - Percentage of free prostate-specific antigen (PSA)

AU - Yi, Yooni

AU - Breau, Rodney H.

AU - Witiuk, Kelsey

AU - Neuberger, Molly M.

AU - Dahm, Philipp

PY - 2013/4

Y1 - 2013/4

N2 - What's known on the subject? and What does the study add? Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood. This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.

AB - What's known on the subject? and What does the study add? Free to total PSA ratios are commonly used as an adjunct to total PSA levels to better define an individual's risk for prostate cancer; however, its strengths and weaknesses are not well understood. This article illustrates the use of likelihood ratios that can be generated from the reported sensitivities and specificities from given free to total PSA thresholds in either increasing or decreasing an individual patient's probability of prostate cancer. Understanding the strengths and limitations of free to total PSA testing will help clinicians anticipate whether its use is indicated or not.

KW - diagnostic test

KW - elevated PSA

KW - evidence-based medicine

KW - percentage of free prostate-specific antigen

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84875833601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875833601&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11446.x

DO - 10.1111/j.1464-410X.2012.11446.x

M3 - Article

C2 - 23106827

AN - SCOPUS:84875833601

SN - 1464-4096

VL - 111

SP - 683

EP - 685

JO - BJU International

JF - BJU International

IS - 4

ER -

Diagnostic tests in urology: Percentage of free prostate-specific antigen (PSA)

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this